|1.||Dembinski, R: 4 articles (03/2001 - 02/2000)|
|2.||Rossaint, R: 4 articles (03/2001 - 02/2000)|
|3.||Max, M: 3 articles (03/2001 - 02/2000)|
|4.||Kuhlen, R: 3 articles (03/2001 - 02/2000)|
|5.||Dalibon, Nicolas: 2 articles (03/2004 - 04/2002)|
|6.||Liu, Ngai: 2 articles (03/2004 - 04/2002)|
|7.||Fischler, Marc: 2 articles (03/2004 - 04/2002)|
|8.||Moutafis, Marc: 2 articles (03/2004 - 04/2002)|
|9.||Pachocki, R: 2 articles (05/2003 - 09/2001)|
|10.||Górecka, D: 2 articles (05/2003 - 09/2001)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
05/01/2003 - "Almitrine treatment of patients with severe COPD and moderate hypoxaemia resulted in a small but significant improvement in PaO(2) over 12 months. "
01/01/1986 - "Almitrine bismesylate is a chemoreceptor agonist which has been shown to improve arterial blood gas values in chronic obstructive pulmonary disease (COPD) patients, possibly through better ventilation/perfusion matching. "
01/01/1983 - "1. Almitrine, an agonist of peripheral chemoreceptors, has been shown to be effective in lowering PaCO2 in patients with chronic obstructive lung disease. "
03/01/1987 - "Among five of these patients who were given almitrine bismesylate, an experimental medication thought to alter ventilation-perfusion relationships in patients with chronic obstructive pulmonary disease, one had improved oxygenation. "
03/01/1983 - "Improvement in ventilation-perfusion matching by almitrine in COPD."
04/01/1983 - "There were greater increases in the response to progressive hypoxia by 78% after 50 mg of almitrine (P less than 0.01) and by 120% after 100 mg (P less than 0.01), which was also significantly greater than the increase after the 50 mg dose (P less than 0.01). "
01/01/1989 - "In the almitrine group (10 subjects), arterial PO2 improved during hypoxia (from 42 +/- 2 to 47 +/- 1 mm Hg, p less than 0.05, mean +/- SEM) and normoxia (from 99 +/- 3 to 104 +/- 2, p less than 0.05). "
01/01/1985 - "This improvement in hypoxia (9%) is negatively related to the initial PaO2 (p less than 0.01) and positively related to almitrine plasma concentrations (p less than 0.05). "
03/01/2004 - "We performed this prospective randomized double-blinded study to assess the ability of almitrine to treat hypoxemia during one-lung ventilation (OLV). "
10/01/1990 - "However, in the remaining four fetuses, in which the response to hypoxia was inhibitory, almitrine caused an inhibition of breathing that lasted 184 +/- 28 min. We conclude that the action of almitrine is like that of hypoxia and that, because it acts specifically on the chemoreceptors, it may prove to be a useful tool in the study of possible central chemoreceptor mechanisms."
|3.||Obstructive Sleep Apnea
12/01/1986 - "These results suggest that almitrine would not be useful in obstructive sleep apnea, yet because almitrine markedly increased VI, f, and VT and decreased TE in unanesthetized sleeping cats the drug may be effective in patients who lack normal central neural respiratory drive, such as the preterm infant."
07/01/1985 - "Previous studies suggest clinical usefulness in the adult with chronic obstructive pulmonary disease, but little data are available to decide whether almitrine would be helpful in diseases involving pharyngeal airway obstruction, such as apnea of prematurity or obstructive sleep apnea. "
|4.||Respiratory Insufficiency (Respiratory Failure)
01/01/1990 - "Thus, almitrine bismesylate can be considered useful in the treatment of patients with chronic respiratory insufficiency."
01/01/1986 - "patients with acute respiratory failure entered this preliminary study to evaluate the effects of almitrine bismesylate against placebo. "
10/04/1984 - "Several studies with a 1 year follow-up have shown that almitrine bismesylate represents a breakthrough in the management of respiratory failure consecutive to chronic obstructive respiratory disease. "
01/01/1980 - "[Therapeutic trial of intravenous perfusion of almitrine in acute attacks of respiratory insufficiency]."
01/01/2002 - "Almitrine is used to improve ventilatory drive and ventilation-perfusion matching in respiratory failure. "
|5.||Peripheral Nervous System Diseases (PNS Diseases)
04/01/1989 - "Three patients developed symptoms and signs of peripheral neuropathy during the 12 months of the study and a fourth developed peripheral neuropathy at 18 months, having continued to receive almitrine. "
03/01/1991 - "Twenty nine patients withdrew from the almitrine group with seven deaths and six cases of peripheral neuropathy, and 22 patients withdrew from the placebo group with six deaths and two cases of peripheral neuropathy. "
03/01/1989 - "Almitrine bismesylate can induce a stereotypical sensory peripheral neuropathy probably through a toxic mechanism. "
01/01/1989 - "Almitrine bismesylate is thought to cause sensory peripheral neuropathy. "
01/01/1989 - "Peripheral neuropathies during treatment with almitrine: report of 46 cases."
|2.||Nitric Oxide (Nitrogen Monoxide)
|6.||2,4-bis(2-acetoxybenzamido)benzoic acid (AB 50)
|7.||Doxapram (Doxapram Hydrochloride)
|9.||Medroxyprogesterone Acetate (Depo-Provera)
|2.||Artificial Respiration (Mechanical Ventilation)
|4.||Positive-Pressure Respiration (PEEP)